Lexicon Pharmaceuticals (LXRX) Gets a Buy Rating from Wedbush

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Lexicon Pharmaceuticals (LXRXResearch Report), with a price target of $17.00. The company’s shares closed last Monday at $3.14.

According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.2% and a 41.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lexicon Pharmaceuticals with a $8.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.39 and a one-year low of $1.13. Currently, Lexicon Pharmaceuticals has an average volume of 2.08M.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LXRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.